We are excited to share that Biocytogen will attend RNATx 2026 from June 24th-26th at the Umass Chan Medical School in Worcester, MA. Come meet our experts at booth #16 to learn how Biocytogen’s humanized mouse models and integrated platforms are advancing RNA therapeutic research across a myriad of diseases.
What is RNATx 2026?
RNATx is an annual symposium hosted by the RNA Therapeutics Institute (RTI). This year’s theme will be From Concept to Clinic, with the program featuring a mix of workshops, speakers, and poster sessions on the latest developments in RNA research and therapeutics. Take this opportunity to form meaningful connections and purposeful collaborations with an international community of RNA professionals!
Event Overview
Date: June 24th - 26th, 2026
Venue: UMass Chan Medical School, 55 N Lake Ave, Worcester, MA 01655
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in Worcester, MA!
